Topline
The Trump administration has removed export restrictions on Anthropic’s latest AI models, the company announced on Tuesday, with plans to reinstate global access for users and corporate customers beginning Wednesday.
Anthropic said it will begin restoring access to Claude Fable and Mythos to customers starting Wednesday.
NurPhoto via Getty Images
Key Facts
Anthropic disclosed on X that the U.S. Department of Commerce has lifted export controls on its Claude Fable 5 and Mythos 5 AI systems.
This action follows a two‑week period during which the government temporarily prohibited foreign nationals, including non‑U.S. employees of Anthropic, from accessing the company’s newest models on national security grounds.
Commerce Secretary Howard Lutnick announced on social media that the administration had collaborated with Anthropic over the past two weeks to evaluate and approve Fable 5, underscoring a commitment to bolster America’s leadership in artificial intelligence.
In a letter to Anthropic, Lutnick highlighted the company’s cooperation in proactively identifying and mitigating security risks linked to the two models.
Anthropic has committed to reporting any malicious use of the models to U.S. authorities.
The letter also cautions that the administration may reinstate restrictions should circumstances shift or if Anthropic does not meet its security commitments.
Crucial Quote
White House Chief of Staff Susie Wiles stated on X: “I appreciate companies across sectors for collaborating with the White House to implement the President’s executive order ‘Promoting Advanced AI Innovation and Security.’ This includes effective efforts in advanced model access and guardrail testing, as well as ensuring security…Our shared priority remains: deploy the best technology swiftly and safely.”
Also Read
- Turkey’s Unlikely Tango Renaissance: Istanbul’s Passion for the Argentinian Dance
- Xi Jinping Emphasizes Global Role of Communist Party During 105th Anniversary Address
- Guardians’ Kahlil Watson Displays Five-Tool Brilliance as Injuries Test Cleveland’s Depth
- Expanding Partnership in Parkinson’s Therapeutic Development


